Larazotide
Also known as: Larazotide acetate, AT-1001
An oral, gut-restricted peptide that antagonizes zonulin signaling to limit gluten-driven intestinal tight-junction permeability in celiac disease.
This page is a structured profile. Narrative evidence, dosing context and FAQs live on the research guide — not duplicated here as a second full article.
- Drug class
- Tight-junction regulator / zonulin antagonist
- Primary targets
- Zonulin / tight junctions
- Dose reference
- Investigational; 0.5 mg orally three times daily in trials
- Half-life
- Minimal systemic absorption (gut-restricted)
- Developer / origin
- Alba Therapeutics / 9 Meters Biopharma
- Reference year
- 2005
- Evidence score
- 2/5 - Investigational — failed pivotal trial
Investigational — failed pivotal trial
Larazotide showed positive phase 2 symptom data at the low 0.5 mg dose, but the pivotal phase 3 CeDLara trial was discontinued for futility in 2022 and it is not approved.
Mostly animal, ex vivo, cell, or indirect evidence.
Evidence basis
- Phase 2b trial in 342 adults met its primary endpoint only at the 0.5 mg dose
- Gluten-challenge trials showed reduced gluten-induced symptoms at low doses
- Phase 3 CeDLara halted for futility (2022)
- Tolerability comparable to placebo; no regulatory approval
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
Larazotide guides
Read the matching guide or adjacent research pages for more context.
Peptide calculators
Use calculators for concentration, unit conversion and repeated-dose accumulation math.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
Lanreotide
Somatuline Depot, Somatuline Autogel
Lanreotide binds with high affinity to somatostatin receptors 2 and 5, mimicking native somatostatin to suppress growth hormone, IGF-1 and various neuroendocrine and gut hormones.
Teriparatide
Forteo, Bonsity, PTH 1-34
Once-daily injection produces intermittent activation of the PTH1 receptor on osteoblasts, preferentially stimulating bone formation over resorption to increase bone mass.
Abaloparatide
Tymlos
Abaloparatide is a PTHrP(1-34) analog that agonizes the PTH1 receptor with preference for its transient RG conformation, activating cAMP signaling to stimulate osteoblast-driven new bone formation.
Calcitonin
Miacalcin, Fortical, salmon calcitonin
Calcitonin activates the calcitonin receptor on osteoclasts to inhibit bone resorption and lower blood calcium, with additional actions on the kidney and gastrointestinal tract.